Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare outcome of adjuvant cisplatin and gemcitabine versus capecitabine
- EligibilityCriteria: Inclusion Criteria:  Age: 20 years and older. Patients with no clinical/radiologic distant metastasis. Tumor type: Invasive ductal carcinoma or invaive lobular carcinoma. Tumor subtype: triple negative patients had operable, primary invasive, noninflammatory early stage I-IIIB TNBC (ER and PR <1%, HER2 score: 0 or 1) Patients with a good performance status (0/1) Patients with adequate hematological, cardiac, renal, and hepatic function  Exclusion Criteria:  Patients who achieve pathologic complete response after neoadjuvant chemotherapy inflammatory breast cancer Breast cancer patients with distant metastasis Patient with hormonal receptor positive /HER2 +ve - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult